Details of the Drug
General Information of Drug (ID: DMXANES)
Drug Name |
N-Phenylbenzo[d]oxazol-2-amine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-phenyl-1,3-benzoxazol-2-amine; 2-benzoxazolamine, n-phenyl-; MLS000564967; CHEMBL1269508; SMR000152172; N-Phenylbenzo[d]oxazol-2-amine; NSC53097; 2-anilinobenzoxazole; Enamine_001986; AC1L6BGG; AC1Q4WEW; 2-(Phenylamino)benzoxazole; Oprea1_506735; Oprea1_258700; cid_243391; SCHEMBL2658434; BDBM49481; BFLIOKCEGCUTNH-UHFFFAOYSA-N; HMS2433J13; HMS1399K06; 1,3-benzoxazol-2-yl(phenyl)amine; ZINC1684315; NSC-53097; BENZOOXAZOL-2-YL-PHENYL-AMINE; AKOS003001295; SC-56852; KB-302380; N-phenyl-2,3-dihydro-1,3-benzoxazol-2-imine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 210.23 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||